Fosfomycin, interesting alternative drug for treatment of urinary tract infections created by multiple drug resistant and extended spectrum β-lactamase producing strains

Fatemeh Yeganeh-Sefidan1,2, Reza Ghotaslou1,2*, Mohammad Taghi Akhi1, Mohammad Reza Sadeghi2, Yalda Mohammadzadeh-Asl2, Hussein Bannazadeh Baghi2

1Tropical and Infectious Diseases Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran
2Department of Microbiology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

ABSTRACT

Background and Objectives: The emergence and spread of multidrug resistant (MDR) and extended spectrum β-lactamase (ESBL) producing strains reduces the number of effective drugs that can be used for treatment. The aim of this study was to evaluate the susceptibility profile of Enterobacteriaceae isolated from UTIs, specifically MDR and ESBL producing strains, to fosfomycin and other antibiotics.

Materials and Methods: The study was performed during a 6 month period (February 2014 to August 2015). A total of 219 non-duplicate urinary isolates of Enterobacteriaceae were collected. Identification and susceptibility testing was done according to standard microbiological procedures and the Kirby-Bauer test, respectively. Based on the results obtained from susceptibility testing, MDR bacteria were recovered and identification of ESBL production was done according to CLSI recommendation.

Results: Isolates of E. coli and Klebsiella spp. were responsible for 80.8% and 12.8% of patients with UTIs respectively. The rates of resistance to ampicillin, cefazolin, nalidixic acid, trimethoprim-sulfamethoxazole were 86.3%, 79.4%, 68.5% and 63.9% respectively. In contrast, high sensitivity rates were detected to fosfomycin, amikacin and amoxicillin-clavulanic acid with 97.3%, 91.8% and 80.8%, respectively. Of all isolates, 167 (76.3%) were detected as MDR and 75 (34.2%) as ESBL producing strains.

Conclusion: The rate of antibiotic resistance among uropathogens Enterobacteriaceae is remarkably high. The most effective antibiotic was fosfomycin. Moreover, susceptibility to fosfomycin is over 90% for MDR and ESBL producer isolates. Therefore, fosfomycin can be a good option for treating UTIs.

Keywords: Enterobacteriaceae, ESBL, Fosfomycin, MDR, UTIs

INTRODUCTION

Urinary tract infections (UTIs) are the most common type of human bacterial infections (1). Over 150 million cases of UTIs occur annually in the world (2). The main cause of infection in 80-90% of uncomplicated UTIs is E. coli (3, 4). Today, an increase in antimicrobial resistance of UTI pathogens is observed (5). Additionally, the emergence and spread of MDR Gram-negative bacteria associated with UTIs, in the community and hospitals, is increasing in the world (6). MDR was defined as resistance to...
at least one agent of three or more antibiotic classes (7). The number of effective drugs that can be used for treatment of UTIs, through increase of MDR, is reduced (8). Uropathogen bacteria, particularly \textit{E. coli}, exhibit high rates of resistance through production of extended-spectrum \(\beta\)-lactamases (ESBL) (1). Clinically, ESBL confers considerable resistance to broad-spectrum penicillins, monobactams and cephalosporins (except cephemycins), and are often associated with co-resistance to unrelated antibiotics in MDR pathogens (5). Trimethoprim-sulfamethoxazole previously has been used to treat UTIs, due to the increasing occurrence of resistance among uropathogens. Currently, fluoroquinolone are being used frequently as first-line therapy. However, the frequency of ciprofloxacin resistance in \textit{E. coli} has been rapidly increased worldwide (9).

Recently, fosfomycin has been introduced for the treatment of UTIs and systemic infections caused by MDR Gram-negative bacteria, especially Enterobacteriaceae that are resistant to traditional antimicrobial agents (10). Fosfomycin is a broad spectrum bactericidal antibiotic that interferes with cell wall synthesis in both Gram-negative and Gram-positive bacteria (11). There are a few studies on the \textit{in vitro} activity of fosfomycin against commonly encountered bacteria isolated from the urine, except for \textit{E. coli} and \textit{E. faecalis} (12). The aim of this study was to investigate the susceptibility of isolates to eight genera belonging to Enterobacteriaceae family cultured from patients with UTIs, in particular MDR and ESBL producers, to fosfomycin.

**MATERIALS AND METHODS**

**Bacterial isolates.** A total of 219 non-duplicate urinary isolates of Enterobacteriaceae were collected during February 2014 through August 2015 from two cities of Iran; Tabriz (117 Sample) and Uremia (102 Sample). Isolates were identified using biochemical tests in the Department of Microbiology, Tabriz University of Medical Sciences, Iran.

**Antimicrobial susceptibility testing.** The antimicrobial susceptibility testing was performed on Mueller – Hinton agar using Kirby-Bauer’s technique according to the Clinical and Laboratory Standards Institute’s (CLSI) guidelines (12). The antibiotic discs used for antimicrobial susceptibility testing were as follows: amoxicillin-clavulanic acid (20/10µg), ampicillin (10µg), cefotaxime (30µg), ceftazidime (30µg), cefepime (30µg), cefuroxime (30µg), aztreonam (30µg), gentamicin (10 µg), amikacin (30µg), ciprofloxacin (5µg), nalidixic acid (30µg), trimethoprim-sulfamethoxazole (30µg), nitrofurantoin (300µg) and fosfomycin (200µg). All antibiotics, except fosfomycin (Rosco, Taastrup, Denmark), were obtained from MAST (MAST Chemical Co, UK). \textit{E. coli} ATCC 25922 and \textit{P. aeruginosa} ATCC 27853 strains were used for quality control. Isolates that were resistant to at least one agent of three or more classes of antibiotic were considered as MDR.

**ESBL detection.** The screening test for the identification of ESBL production was done according to CLSI recommendations. An inhibition zone of 22≥ mm for ceftazidime and 27≥ mm for cefotaxime indicated the possibility of ESBL producing isolate. The confirmatory test for ESBL was performed using double disc synergy between amoxicillin-clavulanic acid (20/10µg), cefotaxime (30µg) and ceftazidime (30µg). Amoxicillin-clavulanic acid was placed in the center of the plate, which was already inoculated with the test organism, and cefotaxime and ceftazidime discs were placed 20mm (center to center) apart from the amoxicillin-clavulanic acid on the same plate. Organisms that showed synergy effects (extension zone of inhibition around cephalosporin discs on the side nearest to the amoxicillin-clavulanic acid) were considered as positive for ESBL phenotype (13). \textit{E. coli} ATCC 25922 (ESBL negative) and \textit{K. pneumoniae} ATCC 700603 (ESBL positive) were used as quality control strains in the phenotypic testing of ESBL production.

**Statistical analyses.** The results were analyzed using SPSS software for Windows (version 19 SPSS Inc., Chicago, IL, USA). In this study, \(p≤0.05\) was regarded as statistically significant.

**RESULTS**

In the current study, a total of 219 Enterobacteriaceae from urine samples were collected. \textit{E. coli} was the most frequently isolated bacteria. The frequency of bacterial isolates were \textit{E. coli} (n= 177, 80.8%), \textit{K. pneumoniae} (n= 28, 12.8%), \textit{E. cloacae}
(n= 7, 3.2%), *P. mirabilis* (n= 2, 0.9%), *M. morgani* (n= 1, 0.5%), *K. oxytoca* (n= 1, 0.5%), *C. freundii* (n= 1, 0.5%), and *P. vulgaris* (n= 1, 0.5%). Out of 219 sample, 141 (64.4%) and 78 (35.6%) cases were related to females and males samples, respectively. There was a significant relationship between the UTIs and gender (Pv≤0.05). Patient ages ranged from 1 to 93 years. The age distribution of patients was 7.3% for children (1-15), 53% for middle aged patients (16-60) and 39.7% for old aged patients (61-93 years). The resistance rates were different between ages and gender but there was no significant relationship between antimicrobial resistance and age groups and gender (pv>0.05).

The rates of antimicrobial resistance are shown in Table 1 and Fig. 1. According to the results, the highest rate of resistance was in the penicillin group (ampicillin) with 86.3%, followed by the cephems group (cefazolin) with 79.4%, the quinolones group (nalidixic acid) with 68.5% and the folate pathway inhibitors with 63.9%. In contrast, higher sensitivity rates were discovered in fosfomycin with 97.3%, the β-lactam/β-lactamase inhibitors group (amoxicillin-clavulanic acid) with 91.8% and in the aminoglycoside group (amikacin) with 91.8% and in the β-lactam/β-lactamase inhibitors group (amoxicillin-clavulanic acid) with 80.8%. The rate of MDR recovered bacteria was 76.3% (n=167). The most prevalent MDR patterns belonged to the isolates showing resistance to ampicillin, cefazolin, nalidixic acid, trimethoprim-sulfamethoxazole, cefuroxime and ciprofloxacin. Furthermore, 34.2% of isolates (n=75) were found as ESBL producers. Of all ESBL producing isolates, 60 (80%) and 15 (20%) were *E. coli* and *K. pneumoniae*, respectively. The antimicrobial susceptibility patterns of MDR and ESBL producing isolates are shown in Figs. 2 and 3. According to the results, fosfomycin was also the most effective antibiotic against all MDR and ESBL producing isolates followed by amikacin, amoxicillin-clavulanic acid and nitrofurantoin.

**DISCUSSION**

In the present study, we investigated the susceptibility profile of *Enterobacteriaceae* isolated from urinary tract, specifically MDR and ESBL producing isolates, showing resistance to ampicillin, cefazolin, nalidixic acid and nitrofurantoin.

**Table 1. Distribution of resistance patterns of *Enterobacteriaceae* isolates to various antimicrobial agents**

| Antimicrobial agents | Fosfomycin | β-lactam/β-lactamase inhibitors | Nitrofuran | Aminoglycoside des | Cepheims | Monobactams | Quinolones | Folate pathway inhibitors | Penicillin |
|----------------------|------------|--------------------------------|------------|-------------------|----------|-------------|------------|--------------------------|-----------|
|                      | E.coli n(%)| K. pneumonia n(%) | E.colae n(%)| K.mirabilis n(%) | M.morganii n(%) | K.Oxytoa n(%) | C.freundi n(%) | K.Oxytoa n(%) | C.freundi n(%) |
|                      | FO         | 21 (1.1)                       | 1 (3.6)    | 1 (14.3)          | 0 (0.0)   | 2 (100)    | 0 (0.0)    | 1 (100)        | 1 (100)   |
|                      | AMC        | 17 (9.6)                       | 16 (57.1)  | 6 (85.7)          | 1 (50)    | 0 (0.0)    | 1 (100)    | 1 (100)        | 0 (0.0)   |
|                      | NI         | 29 (16.4)                      | 18 (64.3)  | 6 (85.7)          | 2 (100)   | 2 (100)    | 0 (0.0)    | 0 (0.0)        | 0 (0.0)   |
|                      | AK         | 12 (6.8)                       | 6 (21.4)   | 0 (0.0)           | 0 (0.0)   | 0 (0.0)    | 0 (0.0)    | 0 (0.0)        | 0 (0.0)   |
|                      | GM         | 60 (33.9)                      | 13 (46.4)  | 3 (42.8)          | 1 (50)    | 0 (0.0)    | 0 (0.0)    | 0 (0.0)        | 0 (0.0)   |
|                      | CZ         | 141 (79.7)                     | 21 (75)    | 6 (85.7)          | 1 (50)    | 2 (100)    | 1 (100)    | 1 (100)        | 1 (100)   |
|                      | CPM        | 58 (32.8)                      | 18 (64.3)  | 3 (42.8)          | 0 (0.0)   | 0 (0.0)    | 0 (0.0)    | 0 (0.0)        | 0 (0.0)   |
|                      | CXM        | 93 (52.5)                      | 17 (60.7)  | 4 (57.1)          | 1 (50)    | 2 (100)    | 0 (0.0)    | 0 (0.0)        | 0 (0.0)   |
|                      | CFO        | 46 (26)                        | 12 (42.8)  | 7 (100)           | 0 (0.0)   | 0 (0.0)    | 0 (0.0)    | 1 (100)        | 0 (0.0)   |
|                      | ATM        | 83 (46.9)                      | 17 (60.7)  | 3 (42.8)          | 0 (0.0)   | 0 (0.0)    | 0 (0.0)    | 0 (0.0)        | 0 (0.0)   |
|                      | NA         | 128 (72.3)                     | 16 (57.1)  | 4 (57.1)          | 0 (0.0)   | 2 (100)    | 0 (0.0)    | 0 (0.0)        | 0 (0.0)   |
|                      | CIP        | 110 (62.1)                     | 15 (53.6)  | 1 (14.3)          | 0 (0.0)   | 0 (0.0)    | 0 (0.0)    | 0 (0.0)        | 0 (0.0)   |
|                      | TS         | 115 (65)                       | 19 (67.8)  | 4 (57.1)          | 2 (100)   | 0 (0.0)    | 0 (0.0)    | 0 (0.0)        | 0 (0.0)   |
|                      | AP         | 152 (85.9)                     | 27 (96.4)  | 6 (85.7)          | 1 (50)    | 0 (0.0)    | 1 (100)    | 1 (100)        | 1 (100)   |

Abbreviations: n(number), fosfomycin (FO), amoxicillin-clavulanic acid (AMC), nitrofurantoin (NI), amikacin (AK), gentamicin (GM), cefazolin (CZ), cefepime (CPM), cefuroxime (CXM), cefotaxime (CFO), aztreonam (ATM), nalidixic acid (NA), ciprofloxacin (CIP), trimethoprim-sulfamethoxazole (TS), ampicillin (AP).
Fig. 1. Distribution of resistance rates of Enterobacteriaceae isolates to different antibiotics

Fig. 2. Antimicrobial resistance patterns of MDR and non-MDR isolates

Fig. 3. Antimicrobial resistance patterns of ESBL positive and ESBL negative isolates
to fosfomycin and other antibiotics. Moreover, we compared the results resistant profile at different gender and age categories.

Urinary tract infections are the most common infectious diseases. Almost 40-50% of women will suffer from UTIs during their lifetime and one-third of women before the age of 24 will require antibiotic therapy for UTIs (14). The high infection rates among females are related to differences between the female and male genitourinary systems in anatomy and micro-flora (15). Females are more prone to UTIs due to anatomical structure i.e. short urethra, close proximity of urinary tract with anal canal (16). In contrast males are less susceptible to UTIs, due to a longer urethra and the presence of antimicrobial substance in prostatic fluid (17). The sex distribution of patients in this study showed females statistically predominant over males; this result is consistent with previous reports (15, 18).

Among age groups, middle aged patients contributed over 50% of UTIs which concurs with previous studies (18). Although no significant difference was found between antibiotic resistance patterns and gender of patients, males showed a high resistance rate to antibiotics.

The most common pathogens recovered were *E. coli* (80.8%) and *Klebsiella* spp. (12.8%), which is similar to previous reports (2, 13-14, 19).

This *in vitro* susceptibility study showed that fosfomycin was highly active against the majority of isolates. In total, 2.7% of the isolates were resistant to fosfomycin. In comparison to *E. coli* (1.1%), *Klebsiella* spp. (3.6%) showed higher rates of resistance to fosfomycin. This is consistent with the findings of the Demir et al. (20). The low level of resistance to fosfomycin among *E. coli* strains probably is due to limited use of fosfomycin for the treatment of uncomplicated UTIs. The susceptibility to fosfomycin has not been widely studied for other Enterobacteriaceae. In our study, the majority of isolates were susceptible to fosfomycin; susceptibility rates for *P. mirabilis, C. freundii, K. oxytoca* and *P. vulgaris* were 100%, and for *E. cloacae* and *M. morganii* was detected in 85.7% and 0%, respectively. These results are partly in concordance with previous reports, which indicated that all *M. morganii* were resistant to fosfomycin (20).

In comparison to tested antibiotics, apart from fosfomycin, amikacin and amoxicillin-clavulanic acid showed relatively high activity against bacterial isolates. In contrast, high rates of resistance to ampicil-
the clinical setting (9). In our study, 33.9% of E. coli and 53.6% of K. pneumoniae isolates produced ESBL. The prevalence of ESBL producing E. coli isolates in our study was lower than a study performed by Ullah et al. (56.9%). (18), and higher than a study conducted by Ko KS et al. (7.8%) (9). The prevalence and distribution of ESBL among microorganisms significantly varies with bacterial species, time and geographical location (27). Antimicrobial resistance to ESBL producing bacteria showed that all bacteria (except 2 E. coli isolated) have emerged as MDR pathogens. This is similar to a reported data from Pakistan (5). The most of ESBL producing isolates were resistant to ampicillin, cefazolin, cefuroxime, nalidixic acid and trimethoprim-sulfamethoxazole.

On the other hand, very low resistance rate was detected among ESBLs producer's isolates to fosfomycin (2.7%) and amikacin (9.3%). However, in the current study, ESBL producing strains showed 97.3% sensitivity to fosfomycin which concur with reports of previous studies (2, 26). Due to the increasing prevalence of infections, caused by resistant bacteria and especially MDR strains, availability of alternative effective antibiotics is restricted. This study, like previous studies (19), showed that fosfomycin can be a suitable drug to treat infections caused by ESBL producers and MDR strains. However fosfomycin is chemically unrelated to other anti-bacterial agents. Due to the unique mechanism of action it may provide a synergistic effect with other antibiotics including β-lactams, aminoglycosides and fluoroquinolone (11). Moreover, fosfomycin is a good option in the treatment of uncomplicated UTIs because of the administration of a single dose per day, a fine safety profile, availability during pregnancy and the effectiveness on the anaerobic gut flora (6).

As a result, for the effective clinical appropriate treatment of UTIs, knowledge on local epidemiology and antibiotic resistance patterns is essential. We recommend annual studies like this research be conducted for determining local trends of resistance antibiotic, and proper and accurate application of drugs can decrease the resistance rates to antibiotics.

In conclusion, we observed high levels of resistance to commonly used antibiotics. The data presented in this study shows that the most effective antimicrobial agent is fosfomycin when compared with other antibiotics against uropathogens Enterobacteriaceae isolates.

ACKNOWLEDGMENTS

This project (number: 93-08) was financially supported by Tropical and Infectious Diseases Research Center, Tabriz University of Medical Sciences. This article was written based in a dataset of Ph.D thesis (number: 93.5-4.8), registered in Tabriz University of Medical Sciences.

REFERENCES

1. Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E, Falagas ME. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother 2009;53:4508-4510.

2. Sultan A, Rizvi M, Khan F, Sami H, Shukla I, Khan HM. Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer? Urol Ann 2015;7:26-30.

3. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003;47:2850-2858.

4. Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Martinez-Ruiz R, et al. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother 2009;64:712-717.

5. Püllükçü H, Aydemir S, Işikgöz Taşbakan M, Çilli F, Tünger A, Ulusoy S. Susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli urine isolates to fosfomycin, ciprofloxacin, amikacin and trimethoprim-sulfamethoxazole. Turk J Med Sci 2008;38:175-180.

6. Demir T, Buyukguclu T. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis 2013;17:e966-970.

7. Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother 2012;56:5744-5747.

8. Lee SY, Park YJ, Yu JK, Jung S, Kim Y, Jeong SH, et al. Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26–composite transposon surrounding fosA3. J Antimicrob Chemother 2012;67:2843-2847.

9. Ko KS, Suh JY, Peck KR, Lee MY, Oh WS, Kwon KT, et al. In vitro activity of fosfomycin against ciproflo-
acin-resistant or extended-spectrum β-lactamase–producing Escherichia coli isolated from urine and blood. 

10. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 2012;67:255-268.

11. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011;15: 732-739.

12. Lu CL, Liu CY, Huang YT, Liao CH, Teng LJ, Turnidge JD, et al. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother 2011;55: 4295-4301.

13. Qureshi M, Asif N, Baig S. Evaluation of extended spectrum β-lactamase mediated resistance in Escherichia coli and Klebsiella in urinary tract infection at a tertiary care hospital. Biomédica 2013;29:78.

14. Khoshbakht R, Salimi A, Shirzad Aski H, Keshavarzi H. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Karaj, Iran. J Microbiol 2012;6:86-90.

15. Amin M, Manijeh M, Pourdangchi Z. Study of bacteria isolated from urinary tract infections and determination of their susceptibility to antibiotics. Jundishapur J Microbiol 2009;3:118-123.

16. Khan IU, Mirza IA, Ikram A, Ali S, Hussain A, Ghaffor T. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria. J Coll Physicians Surg Pak 2014;24:914-917.

17. Farajnia S, Alikhani MY, Ghotoslu R, Naghili B, Nakhlband A. Causative agents and antimicrobial susceptibilities of urinary tract infections in the northwest of Iran. Int J Infect Dis 2009;13:140-144.

18. Ullah F, Malik S, Ahmed J. Antibiotic susceptibility pattern and ESBL prevalence in nosocomial Escherichia coli from urinary tract infections in Pakistan. Adríc J Biotechnol 2009;8:3921-3926.

19. Qiao LD, Chen S, Yang Y, Zhang K, Zheng B, Guo HF, et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open 2013;3:e004152.

20. Demir T, Buyukcu T. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis 2013;17:e966-70.

21. Arslan H, Azap OK, Ergönül O, Timurkaynak F. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005;56: 914-918.

22. Moniri R, Khoshkili A, Akbabi H. Emergence of multidrug resistant strains of Escherichia coli isolated from urinary tract infections. Iran J Public Health 2003;32: 42-46.

23. Garau M, Latorre A, Alonso-Sanz M. Fosfomycin: an underrated antibiotic for urinary tract infections due to Escherichia coli. Enferm Infecc Microbiol Clin 2001;19: 462-466.

24. Dromigny JA, Ndoye B, Macondo EA, Nabeth P, Sihy T, Perrier-Gros-Claude JD. Increasing prevalence of antimicrobial resistance among Enterobacteriaceae uropathogens in Dakar, Senegal: a multicenter study. Diagn Microbiol Infect Dis 2003;47: 595-600.

25. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10: 43-50.

26. Hoşbul T, Ozyurt M, Baylan O, Bektöre B, Ardıç N, Ceylan S, et al. In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections. Mikrobiyol Bul 2009;43: 645-649.

27. Mansouri S, Abbasi S. Prevalence of multiple drug resistant clinical isolates of extended-spectrum beta-lactamase producing Enterobacteriaceae in Southeast Iran. Iran J Public Health 2015;35:101-108.